

Special Issue

Antimicrobial Treatment and Antibiotic Use in Ophthalmology

Message from the Guest Editor

Antimicrobial Treatment and Antibiotic Use in Ophthalmology is a rapidly evolving field that addresses critical challenges in preventing and managing ocular infections. In the context of increasing concerns about antimicrobial resistance and the need for optimized therapeutic strategies, ophthalmology offers unique opportunities for innovation, ranging from targeted drug delivery systems to stewardship programs that balance efficacy with safety. This Special Issue of *Antibiotics* request contributions from researchers, clinicians, and industry experts such as cutting-edge studies, reviews, and case reports that advance our understanding of antibiotic use in ocular care. We encourage you to share your insights and help to shape the future of evidence-based ophthalmic antimicrobial therapy. We are particularly interested in manuscripts from emerging economies that showcase their challenges and efforts in this area.

Guest Editor

Prof. Dr. Mark Willcox

School of Optometry and Vision Science, University of New South Wales, Sydney, NSW 2052, Australia

Deadline for manuscript submissions

31 July 2026



Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



mdpi.com/si/264183

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)





Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of
Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)